Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

BACKGROUND: The efficacy and safety of complement inhibition in COVID-19 patients is unclear. METHODS: A multicenter randomized controlled, open-label trial. Hospitalized COVID-19 patients with signs of systemic inflammation and hypoxemia (PaO(2)/FiO(2) below 350 mmHg) were randomized (2:1 ratio) to...

Descripción completa

Detalles Bibliográficos
Autores principales: De Leeuw, Elisabeth, Van Damme, Karel F. A., Declercq, Jozefien, Bosteels, Cedric, Maes, Bastiaan, Tavernier, Simon J., Detalle, Laurent, Smart, Trevor, Glatt, Sophie, Debeuf, Nincy, Deckers, Julie, Lameire, Sahine, Vandecasteele, Stefaan J., De Neve, Nikolaas, Demedts, Ingel K., Govaerts, Elke, Knoop, Christiane, Vanhove, Karolien, Moutschen, Michel, Terryn, Wim, Depuydt, Pieter, Van Braeckel, Eva, Haerynck, Filomeen, Hendrickx, Tine C. J., Parrein, Vanessa, Lalla, Marianna, Brittain, Claire, Lambrecht, Bart N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361275/
https://www.ncbi.nlm.nih.gov/pubmed/35945604
http://dx.doi.org/10.1186/s12931-022-02126-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361275/
https://www.ncbi.nlm.nih.gov/pubmed/35945604
http://dx.doi.org/10.1186/s12931-022-02126-2

Ejemplares similares